Valneva grabs flu vax approval in Japan; China to supply encephalitis jab to India in U-turn decision;

> Valneva has won approval for its EB66-based prototype influenza vaccine in Japan. Report

> China has flip-flopped on an earlier decision, agreeing to provide India with additional supplies of Japanese encephalitis vaccine for expansion of the Indian government's immunization program. Report

> GeoVax ($GOVX) has appointed Immunovaccine veteran Randal Chase to its board of directors. Release

> Measles vaccination must be scaled up in Ebola-affected countries, the World Health Organization says. More

> Immunovaccine has started a Phase II clinical trial of its DPX-Survivac cancer vaccine in recurrent lymphoma. Release

> Medigene has kicked off a Phase I/II study with DC Vaccine in patients with acute myeloid leukaemia. Release

And Finally... GIV Mobile is partnering up with the International Aids Vaccine Initiative (IAVI) to help fund R&D. More

Suggested Articles

GSK isn't alone in facing a slowdown amid the COVID-19 pandemic, but its big vaccines presence makes 2020 particularly tough for the British pharma.

Experts are divided on whether the U.S. should hold out for an optimal COVID vaccine or accept the best shot it can muster within the next few months.

Sanofi and GSK have agreed to provide 200 million doses of their vaccine to COVAX, a global effort to develop, produce and equitably distribute doses.